eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Vincristine, dactinomycin, and lower doses of cyclophosphamide with or without radiation therapy for patients with newly diagnosed low-risk embryonal/botryoid/spindle cell rhabdomyosarcoma

eagle-i ID


Resource Type

  1. Clinical trial


  1. Intervention
  2. Intervention
  3. Intervention
  4. Intervention
    Radiation therapy
  5. Additional Topic(s)
    Antineoplastic Combined Chemotherapy Protocols
  6. Additional Topic(s)
  7. Resource Description
    Results of past research studies with low-risk rhabdomyosarcoma patients show that using the three chemotherapy medicines (including cyclophosphamide) helps to cure more patients, but cyclophosphamide at the high doses that were used in the past studies can cause late effects.This study is being done to find out the most effective treatment with the least amount of therapy that will still cure patients with low risk rhabdomyosarcoma.
  8. Contact
    Berenberg, Jeffrey
  9. PI
    Wilkinson, Robert, M.D.
  10. Topic
  11. Study Population
    Patient Age: Patients must be < 50 years of age at the time of enrollment. The patient may be 50 years old if that birthday occurs during the period of rapid central review. For patients with: newly diagnosed embryonal rhabdomyosarcoma (RMS), botryoid or spindle cell variants of embryonal RMS, or embryonal ectomesenchymoma. Enrollment on a biology study (COG D9902) to confirm the exact diagnosis is required for all patients.
  12. Website(s)
  13. Funded by
    Children's Oncology Group
  14. Phase
    Phase 3 clinical trial
  15. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016